Ferring Degarelix Prostate Cancer Drug To Launch In First Quarter
This article was originally published in The Pink Sheet Daily
FDA approves the gonadotropin-releasing hormone receptor antagonist, which hasn’t shown the initial surge in testosterone seen with other therapies.
You may also be interested in...
Swiss-drug maker Ferring launched its rapid onset prostate cancer treatment degarelix in the U.S. and Europe in March, marking the firm's first global launch
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.